Kiniksa Pharmaceuticals International (KNSA) Other Operating Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International's Other Operating Expenses history runs 7 years deep, the most recent figure standing at $96.4 million for Q1 2026.

• Quarterly Other Operating Expenses rose 56.3% year-over-year to $96.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $341.9 million (up 55.78% YoY) and the FY2025 annual result came in at $307.2 million, up 62.36% from the prior year.
• Other Operating Expenses was $96.4 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $91.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $96.4 million in Q1 2026 and bottomed at $8.7 million in Q2 2022.
• A 5-year average of $42.9 million and a median of $31.4 million in 2024 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses jumped 317.78% — and 2023, when it increased 22.86%.
• Kiniksa Pharmaceuticals International's Other Operating Expenses stood at $14.2 million in 2022, then jumped by 86.36% to $26.5 million in 2023, then jumped by 149.16% to $66.1 million in 2024, then surged by 37.66% to $91.0 million in 2025, then increased by 5.93% to $96.4 million in 2026.
• Business Quant data shows KNSA's Other Operating Expenses at $96.4 million in Q1 2026, $91.0 million in Q4 2025, and $83.6 million in Q3 2025.